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Summary To evaluate the natural history of a disease and the effects of therapeutic interventions, it is
important to determine which are the causes of treatment failure and to assess the extent to which each cause
contributes to the total failure rate. The paper presents a new biostatistical technique to decompose the total
event-free survival of a diseased population into cause-specific failure rates. The technique was based on a
competing risk approach thereby avoiding biases related to assumptions of independence between different
types of event. Such assumptions are inherent in the conventional Kaplan-Meier or actuarial methods. The
competing risk method was used to analyse the pattern of failure among 2,850 pre- and postmenopausal
patients with early-stage breast cancer and the results were compared to those obtained using conventional
methods. The following events were analysed: loco-regional recurrence, distant metastasis, contralateral breast
cancer, other new primary malignancies, and intercurrent deaths. The rate of new primary malignancies was
found to be significantly higher in post- than in premenopausal patients (6% vs 3% at 10 years). In low-risk,
node-negative postmenopausal patients the incidence of recurrences from breast cancer were found to be no
greater than other types of events. This observation highlights the significance of the effect of different
adjuvant therapies not only on the disease itself but also on the risk of second primary malignancies and other
intercurrent diseases. In general, it was found that the conventional statistical methods tended to overestimate
the event-specific rates. In conclusion, the method based on competing risks permits an unbiased analysis of all
types of events determining the total event-free survival. It is thus useful for the description of the natural
history of breast cancer as well as other diseases.
Adjuvant treatments in early breast cancer have been widely
evaluated in randomised trials in the last years. The two most
commonly used endpoints are overall survival and relapse-
free survival which includes local recurrence, distant metas-
tasis or death as endpoints. Kaplan-Meier and actuarial
methods for estimating local recurrence or distant metastasis
rates has been frequently used to analyse patterns of failure
separately for each failure type. Recently, this procedure has
been criticised for possible biases in the estimation of event
rates (Gelman et al., 1990). The most important criticism is
that different failure types are assumed independent.
Moreover, recurrences are usually emphasised in assessing
adjuvant treatments and other tumour events such as new
primary malignancies or contralateral breast cancer are often
ignored. A more appropriate solution to estimate event rates
whatever the type is to evaluate cumulative incidence func-
tions by taking into account other events within a competing
risk framework (Gelman et al., 1990; Castiglione et al., 1990;
Kramar et al., 1987, 1990).
The purpose of this paper is to report results in terms of
event-free survival, obtained in 2,850 patients with early
breast cancer included in two randomised trials of adjuvant
treatment, using a competing risk approach to estimate pro-
babilities of local recurrences, distant metastases, cont-
ralateral breast cancers, other new primary malignancies and
deaths unrelated to cancer. Event-specific cumulative rates
were estimated by cumulative incidence functions
(Kalbfleisch & Prentice, 1980) and incorporated in a com-
puter program developed at the Institut Gustave-Roussy.
Since the frequency of first event types may vary according
to prognostic status, different patterns of failure were
analysed in three groups of patients: premenopausal with
high risk disease, postmenopausal with high and low risk
disease, defined according to a priori combinations of risk
factors. Results obtained by the competing risk method were
compared to those obtained by conventional methods.
Patients and methods
Design ofthe trials
The trials were initiated in 1976 and included 2,850 pre- and
postmenopausal patients aged under 71 years with a
unilateral, operable breast cancer. Patient accrual started in
October 1976 and 2,850 women were entered in the trials up
to December 31, 1988. Patients randomised between January
1989 and May 1990, when the trials were closed, were not
included in this analysis. The end date for follow-up was
December 31, 1989. The mean follow-up time was 6.7 years.
Nine patients (0.3%) emigrated and were considered lost to
follow-up.
Patients with a history of cancer were not eligible for the
trials. Surgery consisted of a modified radical mastectomy
(2,521 patients) or of a partial mastectomy with axillary
dissection followed by local radiotherapy (329 patients). The
first trial compared postoperative radiotherapy to adjuvant
chemotherapy in high risk pre- or postmenopausal patients,
the second trial compared tamoxifen versus no tamoxifen in
high and low risk postmenopausal patients. As many post-
menopausal patients were eligible for both concurrent trials,
they were included in a 2 x 2 factorial design.
Three groups of patients defined a priori according to risk
factors and menopausal status were included. The first group
included 485 premenopausal women with high risk of recur-
rence. These women were required to have either his-
tologically verified lymph node metastases or a tumour
diameter, measured on the surgical specimen, exceeding
30 mm. Patients were randomised between postoperative
radiotherapy or adjuvant chemotherapy. The second group
included 850 postmenopausal women with the same high risk
factors of recurrence. Six hundred twenty-eight patients aged
under 66 years were randomised between radiotherapy or
chemotherapy. They were also included in the concurrent
randomised comparison of adjuvant tamoxifen versus no
adjuvant hormonal therapy. Two hundred twenty-two
patients aged over 65 years were only included in the latter
randomisation. The third group included 1,515 post-
menopausal women with low risk factors, i.e. tumour
diameter less than 31 mm with histologically negative axillary
lymph nodes. These patients were only included in the latter
randomisation. The resulting treatment groups are shown in
Table I. Because of a temporary shortage of radiation treat-
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ment capacity in the Stockholm area, 2/3 of the patients were
randomised to chemotherapy and 1/3 to radiotherapy during
three years. This explains the different numbers in the
radiotherapy and chemotherapy groups. Main clinical and
histological characteristics of the three risk groups are shown
in Table II.
Radiotherapy was given with megavoltage technique A
dose of 46 Gy was delivered in 23 fractions over 4.5 weeks.
The target volume included the chest wall, axilla, suprac-
lavicular fossa, and the ipsilateral internal mammary chain.
The chemotherapy protocol consisted of 12 courses of CMF
(cyclophosphamide 100 mg m-2 orally on days 1-14,
methotrexate 40 mg m- i.v. on days 1 and 8, 5-fluoruracil
600 mgm2 i.v. on days 1 and 8 (Bonadonna et al., 1976).
Tamoxifen was given post-operatively at a dose of 40 mg
daily for 2 years.
Preliminary results
Details of the adjuvant trials and preliminary results were
published previously (Rutqvist et al., 1987, 1989). Results in
terms of overall survival and relapse-free survival did not
show a significant difference between the chemotherapy and
the radiotherapy groups, but radiotherapy in postmenopausal
patients and chemotherapy in premenopausal patients tended
to be more effective. In the tamoxifen trial, a significant effect
was shown in terms of recurrence reduction but there was
only a minor difference in overall survival. Detailed analyses
on treatment effects assuming competing risks will be pub-
lished separately.
Patients included in the trials were followed regularly in
the oncologic clinics of the Stockholm region according to
the following planned schedule: every 3 months in the first 2
years, every 6 months between 2 and 5 years and yearly after
5 years. Examinations included clinical examination and
yearly mammograms, other examinations being requested
only in case of symptoms.
Registration ofsecond cancers
As previously reported (Fornander et al., 1989) the trial
patients were matched against the Swedish Cancer Registry
by computerised record linkage with their identification
numbers. All new cases of cancer diagnosed after the date of
randomisation were recorded.
Statistical methodology
Event-free survival (EFS) was calculated as the time from
randomisation to local recurrence, distant metastasis, cont-
ralateral breast cancer, other new primary malignancy or
death without cancer whichever came first. The occurrence of
the first of any one of these five events determined the overall
event rate (ER), the complementary value being the event-
free survival rate (EFS = 1-ER).
EFS curves were estimated using the Kaplan-Meier
method (Kaplan et al., 1958). Differences between the three
risk groups were compared using the logrank test (Peto et al.,
1977).
Three methods of estimating the incidence of each specific
event type were carried out according to the way in which
other events were taken into account. Other events were
either ignored, censored or included. Details concerning the
estimation procedures are provided in the Appendix.
Ignore method The usual method of estimating event-
specific incidence rates is made by taking one minus the
Kaplan-Meier estimate ignoring all other events. The
incidence estimates so obtained are made in the absence of
other events. For instance, when estimating the metastasis
rate with this method, all occurrences of local recurrence,
contralateral breast cancer or new primary malignancy in
patients experiencing metastases, are ignored. Patients who
do not experience the event of interest are considered at risk
until death or last known follow-up time. This method
Table I Allocated treatment groups according to risk factors, menopausal status and age
Trial Radio Chemo Tamox Risk Status Age n Total
I Yes No - High Pre - 225
No Yes - High Pre - 260 485
I Yes No No High Post -65 133
+ Yes No Yes High Post -65 151
II No Yes No High Post -65 171
No Yes Yes High Post -65 173 628
II Yes - No High Post 66+ 113
Yes - Yes High Post 66+ 109 222
II - - No Low Pre - 760
- - Yes Low Pre - 755 1515
All trials 2850
Table II Clinical and histological characteristics (%) according to risk groups
High risk Low risk
Characteristics Premenopausal Postmenopausal Postmenopausal
(n=485) (n=850) (n= 1515)
Age (Years)
<46 57 0 0
46-55 43 21 16
56-65 0 55 55
>65 0 24 29
Histological Tsize (cm)
<= 3 71 76 100
>3 29 24 0
Histological N
N(-) 12 13 99
I N(+) 26 28 0.3
2N(+) 20 21 0.1
3 N(+) 14 12 0.1
4N(+) 11 9 0.0
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assumes independence between the event of interest and
death and censoring just as the usual Kaplan-Meier estimate
assumes independence between death and censoring in sur-
vival studies. When a particular patient can experience more
than one event type, this method is not really a decomposi-
tion of time to first event since obviously more events are
being analysed.
Censor method Another possible method in decomposing
event-free survival consists in censoring all events other than
the event of interest at the time of their occurrence. Patients
are no longer considered at risk of a specific event once any
other event has occurred first. In this case, the incidence
estimates obtained by the Kaplan-Meier method are made by
mixing all events other than the one of interest with truly
censored observations. Since event times are censored at the
occurrence of other events, this method makes strong
assumptions of independence between all event types. Also,
the sum ofeach individual estimate ofincidence does not add
up to the overall event rate (Appendix).
Include method A third and more appropriate approach to
decompose event-free survival consists in including all events
defining relapse by using cumulative incidence functions.
These incidence estimates subdivide into separate com-
ponents which add up to the overall ER. No assumption of
independence is necessary. In this context, events are con-
sidered as competing risks and the appearance of one type of
event does not censor the appearance of another.
The inadequacies of usual methods of estimation have
been pointed out in a recent article (Gelman et al., 1990) and
a worked example has been provided (Kramar et al., 1990).
Usual methods tend to overestimate specific event rates when
more than one event type is considered. Event rates when
estimated by a competing risk approach reduces biases
related to: (i) the assumption of independence between the
occurrence of local recurrence and distant metastasis; (ii)
exclusion of other events such as new primary malignancy,
contralateral breast cancer and intercurrent death in the
determination of the event-free survival; (iii) the fact that a
new primary malignancy may be incorrectly diagnosed as a
metastasis after distant recurrence. Event-specific cumulative
incidence curves were thus estimated from the decomposition
of the EFS curves and a computer program (COMPETE)
developed at the Institut Gustave-Roussy was used for the
calculations.
Results obtained using the competing risk approach were
compared to the method of ignoring or censoring other
events for the data provided here.
Results
The EFS curves for the three groups are shown in Figure 1.
The difference in EFS between the low risk group and both
high risk groups was highly significant (P<0.0001).
The subdivision by type of event using the competing risk
approach are shown in Figures 2a, b and c, and ten-year
estimates are given in the first column of Tables IIIa, b and c
for each risk group respectively. The separate estimates in
column 1 add up to the total 10 year total event rate of
56.1%, 61.8% and 37.4%, respectively, the complementary
value being the EFS.
Local recurrence and distant metastasis rates were, as
expected, significantly lower in the low risk postmenopausal
group (P<0.0001). The incidence of new primary malignan-
cies was significantly higher in both groups of post-
menopausal patients (P = 0.05).
The patterns of failure obtained by using the competing
risk approach in the three risk groups were found to be quite
different. In the high risk premenopausal group, the 10-year
event rates were 34% for distant metastases, 14% for local
recurrence and 3% for new primary malignancies (Table
IIIa). In the high risk postmenopausal group the incidence of







Figure 1 Event-free survival according to three risk groups: high
risk premenopausal, high risk postmenopausal and low risk post-
menopausal.
incidence of new primary malignancies was twice as high
when compared to the high risk premenopausal group. In the
low riskpostmenopausal group the risk of new primary malig-
nancies (6% at 10 years) was similar to that observed in the
high-risk postmenopausal group, and only 10% of local
recurrence and 11% of distant metastasis were observed
(Table IlIc). The incidence of contralateral breast cancer was
approximately 5% at 10 years in all three groups.
These results were compared to methods which censor or
ignore other events. With the censoring method (column 2),
it makes no sense to add the event rates since these estimates
do not have a probability interpretation. They are
systematically greater than the estimates obtained under the
competing risk approach. Also they were obtained by assum-
ing independence between each event type (Appendix). It can
easily be verified that the product of one minus these rates is
equal to the ER rate in the absence of no ties in the event
times. For example, in the high risk premenopausal patients
it can be verified that (1 - 0.164) x (1 - 0.394) x (1 - 0.074)
x (1 - 0.049) x (1 - 0.017) is equal to 0.439, the event-free
survival rate (Table IIIa). These estimates can be considered
as incidence estimates if one is willing to make strong
assumption of independence between all of the event types.
The estimates in the third column were obtained by ignoring
other events. Patients were considered at risk of each specific
event during the whole follow-up time whether or not any
other event occurred. This approach is not an appropriate
method when the interest is in evaluating which events are
contributing to site of first failure. It may give an indication
of the incidence of an overall metastasis rate whether or not
a local recurrence occurred before and/or afterwards.
More detailed results are shown in Figure 3a, b and c for
1,335 high risk pre- and postmenopausal patients in terms of
local recurrence, distant metastasis and second malignancies,
respectively, comparing in each figure the results of ignore,
censor and include methods. Figure 3a and b show that
ignore and censor methods overestimate the probability of
distant metastases and local recurrences, this overestimation
is greater for the ignore method. For second malignancy
(Figure 3c), defined as contralateral breast cancer or other
new primaries, a similar overestimation is observed, but the
ignore and censor methods give similar estimations indicating
that in most cases this event is the first site of failure. Details
on the calculation of local recurrence rates are provided as a
worked example in the Appendix for the same category of
patients.af Tollr-a Hlo Tln-upnr mimilintive incidence rates accordine to three




Event at 10 years (%) events events events
Local recurrence 13.8 16.4 20.5
Distant metastasis 34.0 39.4 45.5
Contralateral breast 4.2 7.4 9.1
New primary malignancy 3.0 4.9 5.1
Intercurrent death 1.1 1.7 -
Death with or without - - 42.3
cancer
Death or any tumour event
rate (ER) 56.1









Table Illb Ten-year cumulative incidence rates according to three




Event at 10 years (%) events events events
Local recurrence 15.7 20.9 25.0
Distant metastasis 32.1 38.1 44.9
Contralateral breast 4.5 8.0 6.9
New primary malignancy 6.4 10.7 11.5
Intercurrent death 3.1 5.1
Death with or without - - 49.8
cancer
Death or any tumour event
rate (ER) 61.8
Event-free survival (%) 38.2 38.2 38.2
Table IIlc Ten-year cumulative incidence rates according to three




Event at 10 years (%) events events events
Local recurrence 10.3 11.9 12.1
Distant metastasis 10.9 12.4 16.7
Contralateral breast 5.6 6.9 6.5
New primary malignancy 6.1 7.6 7.7
Intercurrent death 4.5 5.7 -
Death with or without - - 22.9
cancer
Death or any tumour event
rate (ER) 37.4
Event-free survival (%) 62.6 62.6 62.6
Discussion
To evaluate the natural history of a disease and possible
therapeutic improvements, it is necessary to know which
types of failure are operating and to what extent each com-
ponent contributes to overall failure. Cumulative incidence
rates allowing for competing risks provide an estimate of the
first cause of failure in terms of probability.
In evaluations of event-specific incidence functions, the
_ usual practice has been to separately estimate Kaplan-Meier
curves for each event of interest and then take the comple-
l l I I l l l l ll'a" ^ v n f 1b o r%r.... o;necenA!iu,tAv,finnrAr Ti to>lr
0 2 4 6 8 10 menLary IunciLLon as an estLmate oi in;UenI;. i nis proc;cuur
Years (ignore method) is valid when only one event, such as death,
or a group of events, such as relapse, is of interest, since all
Figure 2 Cumulative incidence of first site of failure using the other events are ignored at the time of their occurrence. The
include method for a, high risk premenopausal patients; b, high disadvantage of ignoring other events is that these ignored
risk postmenopausal patients: c, low risk postmenopausal events are usually analysed separately anyway (Tables III,
patients. column 3). If only one type of event were possible, then these
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estimates would correspond to estimates obtained by suppos-
ing that all other event type had been eliminated (usually
referred to as net estimates). The disadvantage of censoring
events other than the one of interest is that strong indepen-
dence assumptions are formulated between each event type

























procedure, the addition of each individual event rate will not
equal the total event rate. However, in the case of no ties in
the data and because of independence between event types,
the product of one minus these estimates should correspond
to the overall EFS rate.
The comparison of the three methods showed that the
event rate estimates obtained by ignoring competing risks can
be highly inaccurate, especially for the high risk groups
where the inaccuracy in the 10-year rates was greater than
5% (Figure 3). In cohort studies these rates can be used to
estimate the number of cases developing a particular event
within a specified time. The ignore method would be more
appropriate in this case, since this method provides an
estimate for the overall event rate and not just the rate of
occurrence of the first event.
When we assumed competing risks among low risk
patients, the 10-year total rate of contralateral breast cancer,
new primary malignancy and intercurrent death was as high
as the total rate or recurrence, approximately 20% (Figure
2a). The former events are often ignored when reporting
treatment results. However, because of their relative fre-
quency, half of all events, they can significantly influence the
EFS. In high-risk patients, local and distant recurrences
represented approximately 80% of all events determining
EFS and distant metastases were twice as frequent as local
recurrences. On the other hand, in low-risk patients local
recurrences were as frequent as distant metastases. The
observation that the incidence of recurrences from breast
cancer were no greater than the incidence of other types of
events among the postmenopausal low-risk patients high-
lights the significance of the effect of different adjuvant
therapies on the risk of second primary malignancies and
other intercurrent diseases. Such effects - be they beneficial
or detrimental - may prove to be as important or even more
important for the long-term outcome than the expected treat-
ment benefit in terms of reduction of breast cancer recur-
rences.
A high incidence of events other than local or distant
recurrence can also be of relevance in sample size calcula-
tions because the treatment effect on recurrence will be
diluted in low-risk patients and it would therefore be appro-
priate to take into account the other event rates in the
calculation of sample size.
The estimation of cumulative incidence rates in the
presence of competing risks has not yet been widely applied
in the literature, as specific statistical packages are not widely
available. In previous studies we have shown that using
conventional methods the incidence of specific events can be
overestimated and their relative importance can be overshad-
owed, such as new primary malignancies in early breast
cancer (Arriagada et al., 1991) or local failure in limited
small cell lung cancer (Arriagada et al., 1992). A wider use of
competing risk analyses will permit to evaluate to what
extent such estimates will differ from those provided by
conventional methods.
In conclusion, the competing risk approach permits an
analysis of all events simultaneously intervening in the deter-
mination of EFS and a more accurate definition of patterns
of first failure. This methodology in conjunction with con-
ventional methods offers a valuable tool in the description of
the natural history of early breast cancer and of possible
treatment effects depending on the differences observed.
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Appendix
The estimates obtained for the three methods presented in this paper
can be summarised by comparing the way in which events of other
types are taken into account; they can be either ignored, censored or
included. In order to apply survival methods to data, it is necessary
to define events and time of their occurrence.
The variable Tj represents time until the occurrence of event type j,
and the variable Ej indicates whether or not event of type j occurred.
In the same setting, the variable X represents time until the occur-
rence of the first event among all those defining event-free survival
and the variable Dj indicates whether or not the first event was of
type j. With these definitions, X takes on the minimum value among
all the Ti's, since event-free survival is concerned with time until the
first event. The ignore method will use the variables Tj and Ej to
estimate survival, and the censor and include methods will use the
variables X and Dj. To illustrate the differences between these
methods, local recurrences will be used as an example.
Ignore
The estimates for the occurrence of local recurrence at time t by the
ignore method is simply given by the ratio of number of events
divided by the number of patients at risk at time t:
(Ig)
p (t) =e(t)/(n(t)
Here e(t) is the number of local recurrences observed at time t, and
n(t) is the number of patients at risk of a local recurrence at time t.
Patients are considered at risk of experiencing a local recurrence up
until no more information is available (lost to follow-up) or until
death occurs. The occurrence of any other event is totally
ignored.
The cumulative local recurrence-free rate at time t by the ignore
method is obtained from the Kaplan-Meier estimate by taking the
product of one minus these conditional probabilities from time u = I
to u =t:
(1g) t (Ig) S (t)= II [I - p (u)]
u=l
The cumulative incidence of local recurrence by the ignore method
at time t is obtained by taking one minus this quantity:
QUg) (t) =1-S (g) (t)
It can be seen that this method treats deaths in exactly the same
way as censored observations when no local recurrence occurs. It is
important to note that the number of patients at risk is, in general,
different for each event type when different event types such as local
recurrences or metastases can occur in succession or simultane-
ously.
The disadvantage of the ignore method is that the ignored events
will eventually be of interest anyway and analysed separately. Also,
patients may experience several event types at the same time or in
succession, and ignoring other events no longer corresponds to a
decomposition of the event rates. It is not reasonable to consider the
ignore method as a means of decomposing event-free survival.
Censor
Another approach to decomposing the event-free survival rate can be
made by considering only first events since event-free survival esti-
mates only consider the first event. The estimates for the occurrence
of local recurrence at time x by the censor method is simply given
by:
p ( (x) = d(x)/(n(x)
where d(x) is the number of local recurrences at time x when local
recurrences appear as a first event, and n(x) is the number ofpatients
at risk of a local recurrence at time x; the variable x representing
time until the first event.
Patients are considered at risk of experiencing a local recurrence
up until no more information is available (lost to follow-up) or until
death occurs or until any event defining event-free survival is ob-
served, whichever come first. The occurrence of any other event is
censored at the time of its occurrence. The difference with the ignore
method is that less events are taken into account and time is limited
to the time of observance of any event no matter what its type. For
example, when metastases are observed for a particular patient, that
patient is no longer considered at risk of a local recurrence and vice
versa.
The cumulative local recurrence-free rate at time x by the censor
method is obtained from the Kaplan-Meier estimate by taking the
product of one minus the conditional probabilities from time u= I
to u=x:
(Ce~ x (Ce) S (x)= n [1-p (u)]
u=l
The cumulative incidence of local recurrence by the censor method
at time x is obtained by taking one minus this quantity:
(Ce) (Ce)
Q (x) = 1-S )(x)
The number ofpatients at risk at a particular time x is the same as
when overall event-free survival is estimated since only the first event
is of interest. However, it can be seen from the definition of the risk
set that the estimates of local recurrence at time x are made by
considering all events other than the one of interest in exactly the
same way as truly censored observations. This implies a strong
assumption of independence between all event types. This can be
seen from the fact that the product of each event-specific survival
estimate is equal to the overall event-free survival estimate SEFS(x) at
time x where:
x (Ce)
SEFS(X) = IT [1 - pj (u)]
u=l
with pj representing the estimate of occurrence of each specific event
included in the definition of overall event-free survival.
The censor method has the advantage of counting events only
once for each patient as in event-free survival, but has the disadvant-
age of making strong assumptions of independence between events
types. Also, the individual incidence estimates do not add up the
overall event-free incidence estimates and this method tends to
overestimate the occurrence of event types.COMPETING RISKS IN EARLY BREAST CANCER 957
Include
A third and more appropriate approach can be made by using
cumulative incidence estimates to decompose overall event-free sur-
vival. Each event type is only counted once as in overall event-free
survival and the risk set is the same. The estimates for the occurrence
of local recurrence at time x is given by p(C)(x) evaluated from the
censor method. The incidence of local recurrences at time x is equal
to the conditional probabilities weighted by the overall event-free
survival in the previous time interval {x-) (Kalbfleisch & Prentice,
1980):
(In) (Ce)
q (x) = [(1 - p (X))SEFs(x-)]
and the cumulative incidence of local recurrence is given by the sum
of these individual incidence estimates in all previous time inter-
vals:
(In) X (Ce)
Q (x) = I [(1 -P (U))SEFS(U-)I
u=O
It can be shown after a few mathematical steps that when cumu-
lative incidence estimates are obtained in this way for each specific
event type, then the overall event-free incidence at time x decom-
poses into a sum of the individual cumulative incidence functions for
each event type.
Example
The following table provides a summary of event types occurring in
the 1335 high risk pre- and postmenopausal patients. Numerical
calculations are only provided for the censor and include methods.
The data are grouped into intervals for the purposes of comparison.
The estimates are Kaplan-Meier estimates. In this case, true censored
observation in a specific interval are considered at risk of any event
for the entire interval. The graphs presented in Figure 3 however,
take into account the actual observed event times.
T N LR OE TC PLR POT SEFS Q(Ce) Q(In)
0 1335 1.000 0.000 0.000
0-1 1335 44 99 14 0.0330 0.1071 0.893 0.033 0.033
1-2 1178 50 100 98 0.0424 0.1273 0.779 0.074 0.071
2-3 930 27 76 87 0.0290 0.1108 0.693 0.101 0.093
3-4 740 16 55 87 0.0216 0.0959 0.626 0.120 0.108
4-5 582 11 41 80 0.0189 0.0893 0.570 0.137 0.120
5-6 450 8 28 56 0.0178 0.0800 0.525 0.152 0.130
6-7 358 3 17 57 0.0084 0.0559 0.495 0.159 0.135
7-8 281 1 12 55 0.0036 0.0463 0.473 0.162 0.137
8-9 213 2 6 48 0.0094 0.0376 0.455 0.170 0.141
9-10 157 1 10 28 0.0064 0.0701 0.423 0.176 0.144
N: Numberofpatientsatrisk ofanyeventatthestartoftimeinterval
T. LR: Number of Local Recurrences observed in time interval T.
OE: Number ofOther Events (Metastases, 2nd primary malignancies,
Contralateral breast, Death) observed in time interval T. TC: Number
ofTrue Censored Observations observed in time interval T. PLR: Con-
ditional probability offailure from local recurrence in time interval T.
POE: Conditional probabilityoffailurefromothereventsintimeinterval
T. SEFS: Event-free survival at theend oftime interval T. Q(C): Estimate
ofcumulative incidence ofLocal recurrence (Censor) at theend oftime
interval T. Q(n): Estimate ofcumulative incidence of Local recurrence
(Include) at the end of time interval T.